Literature DB >> 19115651

Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study.

T J Morgan1, G Power, B Venkatesh, M A Jones.   

Abstract

Fluid-induced metabolic acidosis can be harmful and can complicate cardiopulmonary bypass. In an attempt to prevent this disturbance, we designed a bicarbonate-based crystalloid circuit prime balanced on physico-chemical principles with a strong ion difference of 24 mEq/l and compared its acid-base effects with those of Plasma-Lyte 148, a multiple electrolyte replacement solution containing acetate plus gluconate totalling 50 mEq/l. Twenty patients with normal acid-base status undergoing elective cardiac surgery were randomised 1:1 to a 2 litre prime of either bicarbonate-balanced fluid or Plasma-Lyte 148. With the trial fluid, metabolic acid-base status was normal following bypass initiation (standard base excess 0.1 (1.3) mEq/l, mean, SD), whereas Plasma-Lyte 148 produced a slight metabolic acidosis (standard base excess -2.2 (2.1) mEq/l). Estimated group difference after baseline adjustment was 3.6 mEq/l (95% confidence interval 2.1 to 5.1 mEq/l, P=0.0001). By late bypass, mean standard base excess in both groups was normal (0.8 (2.2) mEq/l vs. -0.8 (1.3) mEq/l, P=0.5). Strong ion gap values were unaltered with the trial fluid, but with Plasma-Lyte 148 increased significantly on bypass initiation (15.2 (2.5) mEq/l vs. 2.5 (1.5) mEq/l, P < 0.0001), remaining elevated in late bypass (8.4 (3.4) mEq/l vs. 5.8 (2.4) mEq/l, P < 0.05). We conclude that a bicarbonate-based crystalloid with a strong ion difference of 24 mEq/l is balanced for cardiopulmonary bypass in patients with normal acid-base status, whereas Plasma-Lyte 148 triggers a surge of unmeasured anions, persisting throughout bypass. These are likely to be gluconate and/or acetate. Whether surges of exogenous anions during bypass can be harmful requires further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19115651     DOI: 10.1177/0310057X0803600611

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  8 in total

1.  The Stewart approach--one clinician's perspective.

Authors:  T John Morgan
Journal:  Clin Biochem Rev       Date:  2009-05

2.  Intraoperative Cell Saving: Is the Solution the Actual Problem?

Authors:  Krishnan Pillay; Shobashini Perumal
Journal:  J Extra Corpor Technol       Date:  2021-03

3.  Plasma acetate, gluconate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte 148 with a bicarbonate-balanced solution.

Authors:  Paul G Davies; Balasubramanian Venkatesh; Thomas J Morgan; Jeffrey J Presneill; Peter S Kruger; Bronwyn J Thomas; Michael S Roberts; Julie Mundy
Journal:  Crit Care       Date:  2011-01-14       Impact factor: 9.097

4.  Comparison of the effects of two different formulas of fluids in craniotomy patients.

Authors:  Mohammadali Attari; Shahryar Sane; Akbar Bordbar
Journal:  Adv Biomed Res       Date:  2014-12-12

Review 5.  Crystalloid fluid therapy.

Authors:  Sumeet Reddy; Laurence Weinberg; Paul Young
Journal:  Crit Care       Date:  2016-03-15       Impact factor: 9.097

6.  Plasma-Lyte 148: A clinical review.

Authors:  Laurence Weinberg; Neil Collins; Kiara Van Mourik; Chong Tan; Rinaldo Bellomo
Journal:  World J Crit Care Med       Date:  2016-11-04

7.  Continuous ultrafiltration during extracorporeal circulation and its effect on lactatemia: A randomized controlled trial.

Authors:  Carlos García-Camacho; Antonio-Jesús Marín-Paz; Carolina Lagares-Franco; María-José Abellán-Hervás; Ana-María Sáinz-Otero
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

8.  Balanced forced-diuresis as a renal protective approach in cardiac surgery: Secondary outcomes of electrolyte changes.

Authors:  Heyman Luckraz; Ramesh Giri; Benjamin Wrigley; Kumaresan Nagarajan; Eshan Senanayake; Emma Sharman; Lawrence Beare; Alan Nevill
Journal:  J Card Surg       Date:  2021-08-19       Impact factor: 1.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.